Incyte Corp

Incyte Exec Heeson Lee Sells 111 Shares in Routine Portfolio Move, Company Shares Surge 1.4% Amid Positive EMA Outlook

Heeson Lee’s small February sale of Incyte shares shows disciplined insider trading amid the company’s steady growth and solid oncology pipeline.

Incyte Corp
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

04/02/2026, 22:27

3 minutes to read

Incyte EVP’s Jan. 6 Share Sale: A Routine Tax Move Amid Explosive Oncology Momentum

Incyte insider sale: EVP Issa Khairie’s January 2026 tax‑related share sale shows routine trading, not a confidence dip, amid strong oncology pipeline growth.

Incyte Corp
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

08/01/2026, 22:19

3 minutes to read

Incyte CMO’s Routine Share Sale Signals No Threat to Monjuvi Momentum, Analysts Say

Incyte insider sale by EVP Steven H. Stein shows disciplined portfolio moves, not a warning, amid Monjuvi success and strong growth prospects.

Incyte Corp
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

07/01/2026, 22:21

3 minutes to read